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the gastrointestinal tract and the release rate of the drug 
from the system. Various attempts have been made to 
prolong the residence time of the dosage forms within 
the stomach.[1,2] Prolongation of the gastric residence 
time (GRT) of delivery devices could be achieved by 
promoting adhesion to the mucous membranes,[3] which 
acted by preventing passage of the microspheres through 
the pylorus[4] or by maintaining them in a buoyant fashion 
in gastric juice.[5–7] With regard to the floating devices, 
Innuccelli et al,[8–10] reported that an air-contained multiple-
unit compartment system showed excellent buoyancy in 
vitro and prolonged GRT relative to the controls in vivo in 
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the fed state. However, in the fasted state, the intragastric 
buoyancy of the devices did not influence GRT. Yuasa 
et al,[11] attempted to prepare an intragastric floating and 
sustained-release preparation, which derived its buoyancy 
from the air trapped in the pores of calcium silicate when 
these particles were covered with polymer. Murata et al,[12] 
prepared calcium-induced alginate gel beads that, upon oral 
administration, were capable of floating on gastric juice.
Glipizide is a second-generation sulfonylurea prescribed to 
treat NIDDM (non- insulin-dependent diabetes mellitus). 
Its short biological half-life (3.4 h) and the site of the 
absorption in the stomach necessitates development of 
controlled-release dosage forms that are retained in the 
stomach, which would increase the absorption, improve 
drug efficiency, and decrease dose requirements.[13] An 
objective was to develop a multiparticulate floating delivery 
system, consisting of highly porous carrier material like 
calcium silicate (CS), glipizide as the drug, and Eudragit® 
S (ES) as the polymer, which would be capable of floating 
on gastric fluid and delivering the therapeutic agent over 
an extended period of time. 
MATERIALS AND METHODS
Materials
Glipizide was supplied as a gift sample by Micro Labs, 
(Bangalore, India); CS was purchased from Sigma 
Chemicals (Mumbai, India); and ES (Eudragit® S) was 
received as a gift sample from M/s Rohm Chemische 
GmBH (Fabrik, Germany). Ethanol, dichloromethane 
(DCM), and the other solvents were purchased from SD 
Fine Chemicals (Mumbai, India). All chemicals were of 
analytical-reagent grade and were used as received.
Preparation of glipizide-absorbed CS
CS (1.0 g) was dispersed in 10 mL ethanolic solution 
of glipizide (50 mg) to prepare a slurry. The slurry was 
ultrasonicated for 10 min in an ice bath at 40% voltage 
frequency using a probe sonicator (Soniweld, Imeco 
Ultrasonics, Mumbai, India) to entrap the drug solution 
inside the pores of the porous carrier. The excess ethanolic 
solution was removed by filtration and then by drying 
in vacuum, which resulted in the glipizide-absorbed CS 
powder.[14]
Preparation of floating microspheres
Microspheres were prepared by the emulsion solvent 
diffusion method established by Kawashima et al.[14] as 
follows: The glipizide-absorbed CS was added into the 
polymer solution of ES (1 g) in ethanol and DCM (2:1) 
and sonicated using the probe sonicator (Soniweld). The 
resulting suspension was poured into a 200 mL aqueous 
solution of polyvinylpyrollidine (0.75% w/v) in a 500 mL 
beaker at 40ºC. The emulsion/suspension was stirred at 500 
rpm employing a 2-bladed propeller-type agitator (Remi, 
Mumbai, India) for 3 h. The microspheres were separated 
by filtration using Whatman filter paper (No. 41, Whatman, 
Brentford, UK), washed with water, and dried at room 
temperature in a desiccator for 24 h. The microspheres 
of glipizide without CS (WC) were also prepared using the 
same method for comparative study.
Process variables 
Amount of polymer: 500, 1000, and 1500 mg; stirring 
rate: 250, 500, 750, and 1000 rpm; Temperature of the 
preparation: 20, 30, 40, and 50°C; volume of aqueous 
phase: 200, 300, 400, and 500 mL; solvent ratio (ethanol: 
DCM): 1:1, 2:1, and 3:1; amount of carrier: 50, 100, 150, 
200, and 250 mg. 
Preparation of nonfloating microspheres
Nonfloating microspheres were prepared using the 
procedure reported by Choi et al.:[15] ES (1.0 g) and glipizide 
(50 mg) were dissolved in 10 mL of ethanol/DCM mixture 
(2:1), followed by addition of 1 mL of aqueous phase 
containing 0.25% w/v of Tween 80. The initial water/oil 
(w/o) emulsion was prepared by stirring the mixture for 20 
s. The w/o emulsion was slowly added into 500 mL of corn 
oil, the second oil phase containing 0.02% w/v of Span 
80 as a surfactant, with stirring at 500 rpm at 25ºC. The 
mixture was stirred for 1 h and the hardened microspheres 
were collected by filtration. The collected microspheres 
were washed with n-hexane thrice and soaked in fresh 
hexane with gentle shaking for 24 h. The microspheres 
were separated and then dried in an oven overnight at 50°C.
Characterization of microspheres 
Micromeritic properties 
The microspheres were characterized by their micromeritic 
properties, such as particle size, true density, tapped density, 
compressibility index, and flow properties.[16] The size 
was measured using an optical microscope, and the mean 
particle size was calculated by measuring 200–300 particles 
with the help of a calibrated ocular micrometer. The 
tapping method was used to determine the tapped density 
and percent compressibility index as follows:
Tapped density = mass of microspheres / volume of 
microspheres after tapping
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Here, V and V0 are the volumes of the sample after and 
before the standard tapping, respectively. True density was 
determined using a benzene displacement method. Porosity 
(ε) was calculated using the equation:
 =− × (/ ) 1 100 PP pt
Where Pt and Pp are the true density and tapped density, 
respectively. Angle of repose ∅ of the microspheres, which 
measures the resistance to particle flow, was determined 
by a fixed funnel method and calculated as
tan∅ = 2H/D
Where 2H / D is the surface area of the free standing height 
of the microspheres heap that is formed on a graph paper 
after making the microspheres flow from the glass funnel. 
Morphology 
The external and internal morphology of the microparticles 
and CS were studied by scanning electron microscopy 
(SEM). The samples for SEM were prepared by lightly 
sprinkling the powder on a double adhesive tape stuck to 
an aluminium stub. The stubs were then coated with gold 
to a thickness of about 300 Ǻ under an argon atmosphere 
using a gold sputter module in a high-vacuum evaporator. 
The coated samples were then randomly scanned and 
photomicrographs were taken with a scanning electron 
microscope (Jeol JSM-1600, Tokyo, Japan). 
Drug content 
The drug content of Eudragit® S microspheres was 
determined by dispersing 50 mg formulation (accurately 
weighed) in 10 mL ethanol, followed by agitation with a 
magnetic stirrer for 12 h to dissolve the polymer and to 
extract the drug. After filtration through a 5 μm membrane 
filter (Millipore), the drug concentration in the ethanol 
phase was determined spectrophotometrically at 276 nm 
(Shimandzu 1601, UV-spectrophotometer). Eudragit® S 
and the CS powder did not interfere under these conditions. 
Each determination was made in triplicate. The percentage 
drug entrapment and yield were calculated as follows:[17]
%Drugentrapment
Calculaetd drungcontent
Theoreticald rugconte
=
n nt
Yield
Totalw eigntof floatingm ircoparticles
Tot





×
=
100
%
a al weightof drug polymera nd porous carrier if added ,( )





×100
Floating behavior 
Fifty milligrams of the floating microparticles were placed 
in simulated gastric fluid (pH 2.0; 100 mL) containing 
0.02% w/v Tween 20. The mixture was stirred at 100 
rpm in a magnetic stirrer. After 8 h, the layer of buoyant 
microparticles was pipetted and separated by filtration. 
Particles in the sinking particulate layer were separated by 
filtration. Particles of both types were dried in a desiccator 
until a constant weight was obtained. Both the fractions of 
microspheres were weighed and buoyancy was determined 
by the weight ratio of floating particles to the sum of 
floating and sinking particles.[18]
Buoyancy (%) = Wf (Wf + Ws ) × 100
Where Wf and Ws are the weights of the floating and 
settled microparticles, respectively. All the determinations 
were made in triplicate. 
Swelling index
For estimating the swelling index, the microspheres were 
suspended in 5 mL of simulated gastric fluid USP (pH 1.2). 
The particle size was monitored by microscopy technique 
every 1 h using an optical microscope. The increase in 
particle size of the microspheres was noted for up to 8 h, 
and the percentage of swelling was determined at different 
time intervals by the difference between diameter of 
microspheres at time t (Dt) and initial time (t = 0 [D0]) as 
calculated from the following equation:
Swellingindex
DD
D
to
t
=
−
Differential scanning calorimetry
Differential scanning calorimetric (DSC) measurements 
were carried out on a modulated DSC (Shimadzu DSC-
60 Calorimeter, Tokyo, Japan). Samples of 2–10 mg were 
placed in aluminium pans and sealed. The probes were 
heated from 25°C to 400°C at a rate of 10 K/min under 
nitrogen atmosphere. 
In vitro release studies 
The release rate of glipizide from floating microspheres 
was determined in a United States Pharmacopeia (USP) 
XXIII basket-type dissolution apparatus. A weighed 
amount of floating microspheres equivalent to 50 mg drug 
was filled into a hard gelatine capsule (No. 0) and placed in 
the basket of the dissolution rate apparatus. Five hundred 
millilitres of the SGF containing 0.02% w/v of Tween 20 
was used as the dissolution medium. The dissolution fluid 
was maintained at 37ºC ± 1ºC at a rotation speed of 100 
rpm. Perfect sink conditions prevailed during the drug 
release study. Five millilitre samples were withdrawn at 30 
min intervals, passed through a 0.25 μm membrane filter 
(Millipore), and analyzed spectrophotometrically at 276 nm 
Pandya, et al.: Characterization of porous carrier-based glipizide100   Journal of Young Pharmacists Vol 3 / No 2
to determine the concentration of glipizide present in the 
dissolution medium. The initial volume of the dissolution 
fluid was maintained by adding 5 mL of fresh dissolution 
fluid after each withdrawal. All experiments were run in 
triplicate.[19]
Drug release pattern from microspheres
In order to understand the mechanism and kinetics of 
drug release, the results of the in vitro drug release study 
were fitted with various kinetic equations like zero-order 
(% release vs. t), first-order (log % release vs t), and Higuchi 
model (Mt /M∞ vs. t). In order to define a model which will 
represent a better fit for the formulation, drug release data 
was further analyzed by Peppas equation, Mt /M∞ = k tn, 
where Mt is the amount of drug released at time t and M∞ 
is the amount of drug released at time ∞; thus, the Mt /M∞ 
is the fraction of drug released at time t, k is the kinetic 
constant, and n is the diffusional exponent, a measure of 
the primary mechanism of drug release. R2 values were 
calculated for the linear curves obtained by regression 
analysis of the above plots.[20,21]
RESULT AND DISCUSSION
Formation of microspheres 
The floating microspheres were prepared by the emulsion 
solvent diffusion technique. A solution or suspension 
of Eudragit® S and glipizide with CS in ethanol and 
dichloromethane was poured into an agitated aqueous 
solution of polyvinyl alcohol. The ethanol rapidly 
partitioned into the external aqueous phase and the polymer 
precipitated around dichloromethane droplets. The 
subsequent evaporation of the entrapped dichloromethane 
led to the formation of internal cavities within the 
microspheres. The incorporation of drug-adsorbed CS into 
the formulation may produce a porous structure within the 
microspheres. The ultrasonication produced drug-adsorbed 
CS in a fine state of subdivision. 
A potential advantage of using large volumes of the 
external aqueous phase are the reduction of the required 
stirring times. The solubility of dichloromethane in water is 
1% w/v. With larger volumes (400–500 mL), the diffusion 
of dichloromethane into the aqueous phase, and hence 
solidification of particles, occurred faster as compared to 
that with 200 mL. Thus, particles could be separated after 
shorter stirring times. It was found that a saturated solution 
of polymer produced smooth and high-yield microspheres. 
The undissolved polymer produced irregular and rod-
shaped particles. Preparation at 20°C or 30°C provided 
porous microspheres having higher porosity, with a surface 
so rough as to crumble upon touching. At 40°C, polymer 
and the drug were co-precipitated and the shell was formed 
by the diffusion of ethanol into the aqueous solution and 
simultaneous evaporation of dichloromethane. In contrast, 
microspheres prepared at 50°C demonstrated a single large 
depression at the surface, which was a consequence of 
rapid evaporation of dichloromethane. A portion of the 
polymer solution aggregated into a fiber-like structure as 
it solidified prior to forming droplets or, alternatively, the 
transient droplets were broken before the solidification was 
complete. As ethanol quickly diffused out of the organic 
phase (polymer solution) into the aqueous phase, Eudragit® 
S dissolved in ethanol solidified in fiber-like aggregates. 
It is documented that when the diffusion rate of solvent 
out of emulsion droplet is too slow, microspheres coalesce 
together. Conversely, when the diffusion rate of solvent 
is too fast, the solvent may diffuse into the aqueous phase 
before stable emulsion droplets are developed, causing 
the aggregation of embryonic microsphere droplets. The 
ratio of dichloromethane with ethanol also affected the 
morphology of the microspheres and the best result with 
a spherical shape was obtained when the ratio of ethanol 
to dichloromethane was 2:1. However, the average particle 
size increased and the wall thickness also increased as the 
amount of Eudragit® S increased. When the amount of 
Eudragit® S was 1.5 g in 15 mL of organic phase, it started 
to form aggregates. When the amount of Eudragit® S was 
less than 0.5 g in 15 mL of organic phase, it started to form 
irregular microspheres with some pores. It is obvious that 
the rotation speed of the propeller affects the yield and size 
distribution of microspheres. As the rotation speed of the 
propeller increased from 250 rpm to 1000 rpm, the average 
particle size decreased, while maintaining its morphology. 
The optimum rotation speed for this experimental system 
was 500 rpm, as judged from the results of particle size 
and size distribution and the drug content. 
Micromeritic properties 
The mean particle sizes were 143 μm for CS powder and 
530, 608, 643, 725, and 835 μm for formulations containing 
CS in the range of 50–250mg. The particle size of the 
formulation WC was found to be 179 μm. The tapped 
density values ranged from 0.40–0.68 g/cm3, while their 
true densities ranged between 1.66–1.95 g/cm3 for all the 
formulations, which may be due to the presence of low-
density CS particles in the microspheres. The porosity of 
all the formulations was found to be in the range of 61%–
79%. The compressibility index ranged between 26%–36%. 
All formulations showed excellent flowability as expressed 
in terms of angle of repose (<40°), except in the case of 
CS5, probably due to the higher content of CS. The better 
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flow property indicates that the floating microspheres that 
were produced were non-aggregated [Table 1]. 
Morphology 
CS-based Eudragit® microspheres were predominantly 
spherical in appearance. The porous nature of the CS 
and spherical shape of the microspheres are evident from 
their SEM photomicrographs [Figure 1a and b]. As can be 
seen in the photomicrograph, there are many pores and 
cavities in the microspheres. Low-density drug-adsorbed 
CS particles are clearly visible inside the microspheres, the 
presence of which is what make the microspheres float on 
the simulated GIT fluids.
Percentage buoyancy, drug entrapment, and swelling 
index
The floating test was carried out to investigate the 
floatability of the prepared microspheres. The floating 
ability differed according to the formulation tested and 
the medium used. The microspheres were spread over 
the surface of SGF and the fraction of microspheres 
that settled down as a function of time was quantitated. 
All the CS-based formulations showed good floating 
ability (83% ± 5%). More than 80% of the particles kept 
floating for at least 10 h. The good buoyancy behavior of 
the microspheres may be attributed to the hollow nature 
of the microspheres and the entrapment of CS of low 
true density. Formulation CS4 containing 200 mg CS gave 
the best floating ability (88%) in SGF. Tween 20 (0.02% 
w/v), added to SGF, counteracted the downward pull at 
the liquid surface by lowering surface tension, because 
the relatively high surface tension of simulated gastric 
fluid causes the highest decrease of surface area at the 
air–fluid interface. Floating of microspheres for 10 h was 
considered satisfactory performance. It was also observed 
that the microspheres of larger size showed longer floating 
time [Table 2]. 
The percent drug entrapment of glipizide in all the 
formulations was found to be good (81% ± 4.0%) at all 
levels of drug loading. The high entrapment efficiency 
of glipizide is believed to be due to its poor aqueous 
solubility. The extent of loading influenced the particle 
size distribution of microspheres. When the loading was 
high, the proportion of larger particles formed was also 
high. With 80% entrapment, most of the particles were in 
the size range of 500–1000 μm, which is suitable for oral 
administration. The size of the microspheres formed may 
however be a function of many factors, such as stirring 
speed, viscosity of the dispersed phase and dispersion 
medium, temperature, amount and size of porous carrier, 
etc. Therefore, it is possible to prepare microspheres of 
desired size by varying some of these parameters. From the 
experimentally determined yields it was found that about 
35% microspheres did not contain any porous carrier. 
The basis for this may be the difference in particle size. As 
porous carrier-free microspheres and carrier particles are 
much smaller in size (100–200 μm) than those microspheres 
containing carrier (500–800 μm), they were separated 
during the sieving step.
Similar results were obtained for swelling index. The 
amount of polymer directly affected the solvent transfer 
rate; thus, as the polymer concentration increased the 
swelling index also increased. The swelling index varied 
from 0.866–1.423. Thus, we can conclude that the amount 
of polymer and stirring speed directly affects swelling 
index.
Differential scanning calorimetry 
In order to determine the physical state of drug, i.e., 
whether amorphous or crystalline, before and after floating 
microsphere formulation, DSC examination was conducted 
for the pure drug, the polymer, CS, and the optimized 
formulation. Thermograms of the single component(s) 
and microspheres are shown in Figure 2. A sharp melting 
transition of glipizide (pure) was observed at 207.5°C 
(curve A). CS powder showed a broad peak maximum at 
Table 1: Micromeritic properties of different floating microspheres (n=3)
Formulation 
code
Mean particle size 
(μm)
True density 
 (g/cm3)
Tapped density  
(g/cm3)
Compressibility 
index (%)
Porosity  
(%)
Angle of repose  
(∅)
CS 143 ± 12 1.40 ± 0.10 0.21 ± 0.12 24.1 ± 0.5 87.0 ± 4 46.0 ± 5°
WC 179 ± 19 1.66 ± 0.13 0.68 ± 0.23 25.6 ± 1.7 61.2 ± 5 30.1 ± 7°
CS1 530 ± 20 1.77 ± 0.23 0.40 ± 0.12 26.2 ± 1.1 78.1 ± 8 32.4 ± 8°
CS2 608 ± 16 1.73 ± 0.18 0.44 ± 0.13 27.1 ± 1.4 76.3 ± 1 34.7 ± 3°
CS3 643 ± 19 1.83 ± 0.14 0.51 ± 0.10 29.6 ± 1.2 73.1 ± 3 36.2 ± 2°
CS4 725 ± 18 1.88 ± 0.16 0.55 ± 0.12 33.1 ± 1.3 72.0 ± 7 38.6 ± 5°
CS5 835 ± 21 1.95 ± 0.21 0.57 ± 0.11 35.5 ± 1.8 71.6 ± 5 42.3 ± 1°
WC, floating microspheres of glipizide without carrier; and CS1 to CS5, floating microspheres of glipizide with calcium silicate
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Table 2: Buoyancy, drug entrapment, and in vitro 
release data of different floating microspheres (n=3)
Formulation 
code
CS content 
(mg)
Buoyancy 
(%)
Drug 
entrapment 
(%)
in vitro drug 
release (8th hour) 
(%)
WC
CS1
CS2
CS3
CS4
CS5
0
50
100
150
200
250
71
77
82
84
88
83
71.00
78.76
81.94
83.87
86.00
80.00
71
59
50
47
41
33
WC, floating microspheres of glipizide without carrier; and CS1 to CS5, floating 
microspheres of glipizide with calcium silicate
Figure 2: DSC thermogram of (a) glipizide; (b) CS powder; (c) Eudragit® 
S; (d) calcium silicate–based microspheres of glipizide
Figure 1: Scanning electron photomicrographs; (a) CS-based 
microsphere, and (b) population of microspheres. CS indicates calcium 
silicate
a b
360°C (curve B). Eudragit® S showed a broad transition 
(curve C). A DSC thermogram of optimized formulation 
showed the CS peak at 360°C and one broad peak at 
167°C, which might be the displaced peak of drug (curve 
D), suggesting that the drug is partly dissolved in the 
polymer and partly in the amorphous form and distributed 
throughout the system. Presence of the CS peak in curve 
D also confirms the presence of CS particles inside the 
formulation.
In vitro drug release study 
Release of glipizide from CS-based microspheres was 
evaluated in SGF (pH 2.0). Since the acrylic polymer used 
is not soluble in acidic pH and starts to dissolve only 
above pH 7, microspheres released the glipizide only by 
diffusion in SGF (pH 2.0). The other reason for the slow 
dissolution rate of drug may be attributed to the low 
solubility of glipizide at acidic pH. No burst effect was 
observed from any of these formulations. The release of 
Figure 3: In vitro release of glipizide from various floating microspheres 
in simulated gastric fluid (pH 2.0) (n=3). WC indicates floating 
microspheres of glipizide without carrier; and CS1-5, floating 
microspheres of glipizide with calcium silicate
glipizide from different formulations followed the order: 
WC > CS1 > CS2 > CS3 > CS4 > CS5. The pattern 
also provides an idea about the effect of CS content on 
drug release from the microspheres (i.e., the higher the 
CS content in microspheres, the lower the drug release) 
[Figure 3]. The release mechanism of glipizide from these 
floating microspheres was also evaluated on the basis of 
theoretical dissolution equations including zero-order, 
first-order, Higuchi matrix, and Peppas-Korsmeyer models. 
The regression coefficients and rate constants from in vitro 
release profiles of glipizide in SGF were calculated and are 
reported in Table 3. Release pattern of glipizide in SGF (pH 
2.0) from all floating microspheres followed the Higuchi 
matrix model and the Peppas-Korsmeyer model. Desai   
et al.[5] reported that noneffervescent floating systems 
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Table 3: The regression coefficients and rate constants for release of glipizide from floating microspheres in 
simulated gastric fluid (pH 2.0) (n=3)
Formulation
code
Zero-order model First-order model H-M model P-K model
r K1 r K2 r K3 r K4
WC 0.8720 10.684 0.9799 – 0.164 0.9902 24.671 0.9782 24.539
CS1 0.8523 8.417 0.9564 – 0.114 0.9931 19.493 0.9807 20.780
CS2 0.8652 7.307 0.9488 – 0.093 0.9953 16.907 0.9868 17.099
CS3 0.8674 6.754 0.9457 – 0.084 0.9924 15.611 0.9787 16.332
CS4 0.8629 6.158 0.9362 – 0.075 0.9898 14.235 0.9736 15.114
CS5 0.8563 5.503 0.9247 – 0.065 0.9924 12.738 0.9807 13.499
obeyed the Higuchi model, indicating drug release via a 
diffusion mechanism. 
In view of the potential utility of the formulation, stability 
studies were carried out at 25ºC/60% RH, 30ºC/65% 
RH, and 40ºC/75% RH for 6 months (climatic zone IV 
condition for accelerated testing) to assess their long-term 
(2 years) stability. The protocols of stability studies were 
in compliance with the guidelines in the WHO document 
for stability testing of products intended for the global 
market. After storage, the formulation was subjected to a 
drug assay, floating behavior, and in vitro dissolution studies. 
The analysis of the efficiency of dissolution data, floating 
behavior, and drug content after storage at 25ºC/60% RH, 
30ºC/65% RH, and 40ºC/75% RH for 6 months showed 
no significant changes in the formulations. 
CONCLUSION
The present formulation study of glipizide was performed 
in an attempt to prepare a floating drug delivery system 
consisting of a floating multiple-unit system. Incorporation 
of CS in the microspheres proved to be an effective method 
to achieve the desired release behavior and buoyancy. The 
performance of these formulations was evaluated and 
the effect of various formulation variables was studied. 
The designed system, combining excellent buoyant 
ability and suitable drug release pattern, could possibly 
be advantageous in terms of increased bioavailability of 
glipizide. The major advantages of the system include: 
(i) ease of preparation, (ii) good buoyancy, (iii) high 
encapsulation efficiency, and (iv) sustained drug release 
over several hours. 
The developed formulation overcomes and alleviates the 
drawbacks and limitations of sustained-release preparations 
in the drug-delivery art through the introduction of CS-
based floating microspheres suitable for controlled release 
of drug after oral administration. The microspheres 
could be compressed into tablets, filled into capsules, or 
formulated into oral suspensions for reconstitution.
REFERENCES
1.  Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst 
1993;10:143-95.
2.  Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled release drug 
delivery systems for prolonged gastric residence: An overview. Drug Dev 
Ind Pharm 1996;22:531-9.
3.  Akiyama Y, Nagahara N, Kashihara T, Hirai S, Toguchi H. In vitro and in vivo 
evaluation of mucoadhesive microspheres prepared for the gastrointestinal 
tract using polyglycerol esters of fatty acids and a poly (acrylic acid) 
derivative. Pharm Res 1995;12:397-405.
4.  Fix JA, Cargill R, Engle K. Controlled gastric emptying: Part 3. Gastric 
residence time of a nondisintegrating geometric shape in human volunteers. 
Pharm Res 1993;10:1087-9.
5.  Desai S, Bolton S. A floating controlled-release drug delivery system: In 
vitro-in vivo evaluation. Pharm Res 1993;10:1321-5.
6.  Oth M, Franz M, Timmermans J, Moe¨s A. The bilayer floating capsule: 
A stomach-dried drug delivery system for misoprostol. Pharm Res 
1992;9:298-302.
7.  Whitehead L, Fell JT, Collett JH, Sharma HL, Smith AM. An in vivo 
study demonstrating prolonged gastric retention. J Controlled Release 
1998;55:3-12.
8.  Iannuccelli V, Coppi G, Bernabei MT, Cameroni R. Air compartment 
multiple-unit system for prolonged gastric residence: Part I. Formulation 
study. Int J Pharm 1998;174:47-54.
9.  Iannuccelli V, Coppi G, Sansone R, Ferolla G. Air compartment multiple-
unit system for prolonged gastric residence: Part II. In vivo evaluation. Int 
J Pharm 1998;174:55-62.
10.  Iannuccelli V, Coppi G, Leo E, Fontana F, Bernabei MT. PVP solid 
dispersions for the controlled release of furosemide from a floating multiple-
unit system. Drug Dev Ind Pharm 2000;26:595-603.
11.  Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric 
floating and sustained release preparation: I. Application of calcium silicate 
as a floating carrier. Chem Pharm Bull 1996;44:1361-6.
12.  Murata Y, Sasaki N, Miyamoto E, Kawashima S. Use of floating alginate 
gel beads for stomach-specific drug delivery. Eur J Pharm Biopharm 
2000;50:221-6.
13.  Patel JK, Patel RP, Amin AF, Patel MM. Formulation and evaluation of 
mucoadhesive glipizide microspheres. AAPS Pharm Sci Tech 2005;10: 
E49-55.
14.  Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y. Hollow microspheres 
for use as a floating controlled drug delivery system in the stomach. J Pharm 
Sci 1992;81:135-40.
15.  Choi HK, Lee JH, Park TG. Effect of formulation and processing 
variables on the characteristics of microspheres for water-soluble drugs 
prepared by w/o/o double emulsion solvent diffusion method. Int J Pharm 
2000;196:75-83.
16.  Martin A. Micrometrics. Physical Pharmacy. 4th ed. Philadelphia, PA: Le 
Febiger; 1993 .p. 431-2.
17.  Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. Physicochemical 
properties to determine the buoyancy of hollow microspheres 
(microballoons) prepared by the emulsion solvent diffusion method. Eur J 
Pharm Biopharm 2003;55:297-304.
Pandya, et al.: Characterization of porous carrier-based glipizide104   Journal of Young Pharmacists Vol 3 / No 2
18.  Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. In vitro evaluation 
of floating and drug releasing behaviours of hollow microspheres 
(microballoons) prepared by the emulsion solvent diffusion method. Eur J 
Pharm Biopharm 2004;57:235-43.
19.  Jain SK, Agarwal GP, Jain NK. Evaluation of porous carrier-based floating 
orlistat microspheres for gastric delivery. AAPS Pharm Sci Tech 2006;7:E1-9.
20.  Polli JE, Rehki GS, Augsburger LL, Shah VP. Methods to compare 
dissolution profiles and a rationale for wide dissolution specification for 
metoprolol tartrate tablets. J Pharm Sci 1997;87:690-700.
21.  Wu PC, Tsai MJ, Huang YB, Cheng JS, Tsai YH. In vitro and in vivo 
evaluation of potassium chloride sustained release formulation prepared 
with saturated polyglycolyed glycerides matrices. Int J Pharm 2002;243: 
119-24.
Cite this article as: Pandya N, Pandya M, Bhaskar VH. Preparation and   
in vitro characterization of porous carrier-based glipizide floating   
microspheres for gastric delivery. J Young Pharmacists 2011;3:97-104.
Source of Support: Nil, Conflict of Interest: None declared.
Pandya, et al.: Characterization of porous carrier-based glipizide
Author Help: Online submission of the manuscripts
Articles can be submitted online from http://www.journalonweb.com. For online submission, the articles should be prepared in two files (first 
page file and article file). Images should be submitted separately.
1)   First Page File: 
  Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should 
be included here. Use text/rtf/doc/pdf files. Do not zip the files.
2)  Article File: 
  The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any informa-
tion (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file 
size to 1024 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being 
incorporated in the article file. This will reduce the size of the file.
3)  Images: 
  Submit good quality color images. Each image should be less than 4096 kb (4 MB) in size. The size of the image can be reduced by decreas-
ing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable 
file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a 
good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.
4)  Legends: 
  Legends for the figures/images should be included at the end of the article file.